Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat

NeuroReport

Volumn 8, Issue 2, 1997, Pages 491-496

  Navarro, Miguel ^a   Hernández, Elena ^a   Muñoz, Raúl M ^a   Del Arco, Ignacio ^a   Villanúa, María Angeles ^a   Carrera, M Rocio A ^b   Rodríguez De Fonseca, Fernando ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Anxiety; Behaviour; Cannabinoids; CB1 receptors; Corticosterone; Defensive withdrawal; Plus maze; SR 141716A

Indexed keywords

AMIDE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT; DRUG RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; TIME; WISTAR RAT;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TIME FACTORS;

EID: 0030609879     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199701200-00023     Document Type: Article

References (23)

1. Hollister LE. Pharmacol Rev 38, 1-20 (1986).
2. Fishman MW, Rosenbaum JF, Yabusaki DI et al. Res Commun Subst Abuse 9, 219-226 (1988).
3. Zuardi AW, Shirakawa I, Finkelfarb E et al. Psychopharmacology 76, 245-250 (1982).
4. Onaivi ES, Green MR and Martin BR. J Pharmacol Exp Ther 253, 1002-1009 (1990).
5. Rodriguez de Fonseca F, Rubio P, Menzaghi F et al. J Pharmacol Exp Ther 276, 56-64 (1996).
6. Navarro M, Fernández-Ruiz JJ, de Miguel et al. Behav Brain. Res 5, 37-46 (1993).
7. Devane WA, Dysarz FA, Johnson MR et al. Mol Pharmacol 34, 605-613 (1988).
8. Herkenham M, Lynn AB, Johnson MR et al. J Neurosci 11, 563-583 (1991).
9. Rodriguez de Fonseca F, Fernández-Ruiz JJ, Eldridge JC et al. Pharmacol Biochem Behav 40, 593-598 (1991).
10. Rodriguez de Fonseca F, Villanúa MA, Muñoz RM et al. Neuroendocrinology 61, 714-721 (1995).
11. Devane WA, Hanus L, Breuer A et al. Science 258, 1946-1949 (1992).
12. Weidenfeld J, Feldman S and Mechoulam R. Neuroendocrinology 59, 110-112 (1993).
13. Rinaldi-Carmona M, Barth F, Héaulme M et al. FEBS Lett 650, 240-244 (1994).
14. Gueudet C, Santucci V, Rinaldi-Carmona M et al. NeuroReport 6, 1293-1297 (1995).
15. Santucci V, Storme J-J, Soubrié P et al. Life Sci 6, PL 103-110 (1996).
16. Perio A, Rinaldi-Carmona M, Maruani J et al. Behav Pharmacol 7, 65-71 (1996).
17. Compton DR, Aceto MD, Lowe J et al. J Pharmacol Exp Ther 277, 586-594 (1996).
18. Tsou K, Patrick SL and Walker JM. Eur J Pharmacol 280, R 13-15 (1995)
19. Takahashi LK, Kalin NH, Van de Burgt JA et al. Behav Neurosci 103, 648-654 (1989).
20. Pellow S, Chopin P, File SE et al. J Neurosci Methods 14, 149[-]167 (1985).
21. Rubio P, Rodriguez de Fonseca F, Muñoz RM et al. Life Sci 56, 2169-2176 (1995).
22. Herkenham M and Brady LS. Soc Neurosci Abstr 20, 1676 (1994).
23. Koob GF, Heinrichs SC, Menzaghi F et al. Semin Neurosci 6, 221-229, (1994).